SHL Telemedicine's SmartHeart® Technology to Take Center Stage at Upcoming VPM 2023 Conference
11 Septembre 2023 - 7:34AM
Business Wire
Initial results from the Mayo Clinic HELP-MI and the Imperial
College London TELE-ACS trials to be presented at the Vulnerable
Plaque and Patient Meeting (VPM) 2023.
SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL”
or the “Company”), a leading provider and developer of
advanced personal telemedicine solutions, is pleased to announce
that initial results from trials conducted by the Mayo Clinic (as
part of a previously announced collaboration) and by Imperial
College London will be featured in two upcoming presentations at
the Imperial Vulnerable Plaque and Patient Meeting 2023 (VPM). Both
trials relate to the utilization of SHL's patented and FDA cleared
SmartHeart® 12-lead ECG technology for remote monitoring of post-MI
(heart attack) patients at home.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230910078442/en/
SHL Telemedicine Logo
These presentations are both scheduled during Session 4 on Day 3
(20 September 2023) of the conference, and can be attended
virtually for free:
- Naseer Alshahrani, BSEMS MSc, in collaboration with Dr. Ramzi
Khamis from Imperial College London, will discuss initial
results from the TELE-ACS randomized control study, showcasing the
benefits of telemedicine in post-ACS (Acute Coronary Syndrome)
care; and
- Dr. Joerg Hermann from the Mayo Clinic will discuss
initial results from the HELP-MI randomized control study, that
evaluates the incidence of emergency department visits,
rehospitalizations and MACE (Major Adverse Cardiovascular Events),
and cost–effectiveness over a period of 90 days following the first
hospitalization for heart attack for patients using SmartHeart® 12
lead ECG. Notably, 12 Lead ECG is the gold standard ECG for
diagnosing heart attack.
"For years now, we have established and proven our technology’s
value for Post MI (heart attack) patients, including significant
reductions in mortality and readmission rates. The underlying
hypothesis of the HELP-MI and TELE-ACS trials is that the
telemonitoring of patients at home, with the use of SmartHeart® 12
lead ECG, may decrease general and cardiac emergency department
presentation and hospital readmission rates, and at a lower
healthcare utilization cost compared to patients with standard
therapy alone” said Erez Nachtomy, CEO of SHL Telemedicine. “We are
excited and optimistic that the outcomes of these new studies, in
collaboration with two esteemed healthcare institutions, will
present results that reflect SHL’s accumulated experience in this
field, and that our SmartHeart® platform will have important
clinical implications for telemedicine and remote patient
monitoring.”
Register for free to virtually participate at VPM
2023:
The "Imperial Vulnerable Plaque and Patient Meeting 2023 (VPM)"
is a distinguished think-tank event that brings together
world-leading scientists, clinical leaders, and industry experts to
exchange knowledge in the field of ischaemic heart disease. The
conference will be held virtually on September 18 - 20th, 2023. SHL
Telemedicine is proud to be a SILVER level industry supporter of
this conference. Interested participants can register for free and
view the presentations online. For more details and registration,
please visit:
https://www.millbrook-events.co.uk/event/2e4281fc-e264-4abe-aaa5-52b8b12f79a9/regProcessStep1
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal
telemedicine systems and the provision of medical call center
services, with a focus on cardiovascular and related diseases, to
end users and to the healthcare community. SHL Telemedicine offers
its services and personal telemedicine devices to subscribers
utilizing telephonic and Internet communication technology. SHL is
listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885,
Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT,
ISIN: US78423T2006, CUSIP: 78423T200).
For more information, please visit our website at
www.shl-telemedicine.com.
Forward-Looking Statements
Some of the information contained in this press release contains
forward-looking statements. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those in the forward-looking statements as a
result of various factors. SHL Telemedicine undertakes no
obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230910078442/en/
Fabienne Farner, IRF, Phone : +41 43 244 81 42,
farner@irf-reputation.ch
SHL Telemedicine (NASDAQ:SHLT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
SHL Telemedicine (NASDAQ:SHLT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024